Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Tumors Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Exclusion Criteria:

Treatment and study plan

Anti-angiogenesis

Drug

Anti-angiogenesis

AMG 706

Drug

Anti-angiogenesis

Primary outcomes

Dose limiting toxicity

Time frame: Cycle 1

Secondary outcomes

Dose selection

Time frame: Study completion

Sponsors and collaborators

Lead sponsor

Amgen

Industry

Registry information

Official study title

A Phase 1, First in Human, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 706 in Subjects With Advanced Solid Tumors

Important dates

Study start: 2003
Primary completion: 2006
Study completion: 2006
First posted: Oct 8, 2004
Registry last updated: May 15, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed